04570oam 2200601 450 991013679980332120230621140038.09782889197767(ebook)(CKB)3710000000631124(oapen)https://directory.doabooks.org/handle/20.500.12854/42645(EXLCZ)99371000000063112420191103h20152015 fy| 0engurc|#---|||||txtrdacontentcrdamediacrrdacarrierCancer nanotheranostics what have we learned so far? /edited by João Conde, Pedro Viana Baptista, Jesús M. De La Fuente and Furong TianFrontiers Media SA2016[Lausanne, Switzerland] :Frontiers Media SA,[2015]©20151 online resource (128 pages) illustrations (chiefly colour); digital file(s)Frontiers in ChemistryFrontiers Research TopicsPrint version: Cancer nanotheranostics: what have we learned so far? [Lausanne, Switzerland]: Frontiers Media SA, 2015 288919776X Includes bibliographical references.After a quarter of century of rapid technological advances, research has revealed the complexity of cancer, a disease intimately related to the dynamic transformation of the genome. However, the full understanding of the molecular onset of this disease is still far from achieved and the search for mechanisms of treatment will follow closely. It is here that Nanotechnology enters the fray offering a wealth of tools to diagnose and treat cancer. In fact, the National Cancer Institute predicts that over the next years, nanotechnology will result in important advances in early detection, molecular imaging, targeted and multifunctional therapeutics, prevention and control of cancer. Nanotechnology offers numerous tools to diagnose and treat cancer, such as new imaging agents, multifunctional devices capable of overcome biological barriers to deliver therapeutic agents directly to cells and tissues involved in cancer growth and metastasis, and devices capable of predicting molecular changes to prevent action against precancerous cells... Nevertheless, despite the significant efforts towards the use of nanomaterials in biologically relevant research, more in vivo studies are needed to assess the applicability of these materials as delivery agents. In fact, only a few went through feasible clinical trials. Nanomaterials have to serve as the norm rather than an exception in the future conventional cancer treatments. Future in vivo work will need to carefully consider the correct choice of chemical modifications to incorporate into the multifunctional nanocarriers to avoid activation off-target, side effects and toxicity. Moreover the majority of studies on nanomaterials do not consider the final application to guide the design of nanomaterial. Instead, the focus is predominantly on engineering materials with specific physical or chemical properties. It is imperative to learn how advances in nanosystem’s capabilities are being used to identify new diagnostic and therapy tools driving the development of personalized medicine in oncology; discover how integrating cancer research and nanotechnology modeling can help patient diagnosis and treatment; recognize how to translate nanotheranostics data into an actionable clinical strategy; discuss with industry leaders how nanotheranostics is evolving and what the impact is on current research efforts; and last but not least, learn what approaches are proving fruitful in turning promising clinical data into treatment realities.Frontiers research topics.CancerTreatmentNanostructured materialsHealth aspectsNanoparticlesGene TherapyImmunotherapybioimagingtheranosticsnanomaterialsDrug deliveryNanomedicineCancerPhototherapyCancerTreatment.Nanostructured materialsHealth aspects.616.99406Pedro Viana Baptistaauth1366189Condé JoãoPhD,Baptista Pedro VianaFuente Jesus M. de la1975-Tian Furong1971-UkMaJRUBOOK9910136799803321Cancer nanotheranostics3388690UNINA01297nam2 22003253i 450 UMC009981720231121125912.0900403767520181002d1973 ||||0itac50 baenggrcnlz01i xxxe z01n˜1: The œmanuscript and the textR. D. DaweLeidenBrill1973273 p.25 cm001SBL01234322001 Studies on the text of SophoclesR. D. Dawe1SofocleTragedieTradizione manoscrittaFIRRMLC379301E882.0109DRAMMA E POESIA DRAMMATICA IN GRECO CLASSICO. ORIGINI-500. Storia, descrizione, studi critici21Dawe, Roger DavidSBLV006989070284627Dawe, Roger D.BVEV017366Dawe, Roger DavidDawe, R. D. <Roger David>UMCV297740Dawe, Roger DavidITIT-0120181002IT-FR0017 Biblioteca umanistica Giorgio ApreaFR0017 NUMC0099817Biblioteca umanistica Giorgio Aprea 52S.SIJ. LG1 Soph.Opera.Daw.1 52FLS0000227275 VMB RS A 2014022520140225 52Manuscript and the text3642320UNICAS01426nas 2200421-a 450 99619983800331620240112213020.0(DE-599)ZDB2025213-4(OCoLC)53985961(CKB)111088195224366(CONSER)--2004202402(EXLCZ)9911108819522436620040106b19972002 s-- -engurunu||||||||txtrdacontentcrdamediacrrdacarrierNational law review[Australia] National Law Review[1997?-2002?]Title from journal web page (viewed Jan. 6, 2004).This title is no longer available at the publisher's Web site, archived copies of the publication and it's home page are available as part of the PANDORA archive at the National Library of Australia.1329-5292 NLRLaw reviewsAustraliaLawAustraliaPeriodicalsLawfast(OCoLC)fst00993678Law reviewsfast(OCoLC)fst00994120Australiafasthttps://id.oclc.org/worldcat/entity/E39QbtfRv8PPH7gCqhkJ8DK8bMPeriodicals.fastLaw reviewsLawLaw.Law reviews.JOURNAL996199838003316National Law Review2136055UNISA